Forte Biosciences Files 8-K
Ticker: FBRX · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1419041
Sentiment: neutral
Topics: 8-K, financial-reporting, operations
TL;DR
Forte Biosciences dropped an 8-K on 3/18, check financials and operations.
AI Summary
Forte Biosciences, Inc. filed an 8-K on March 18, 2024, reporting on results of operations, other events, and financial statements. The company, formerly known as Tocagen Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides an update on Forte Biosciences' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing reporting on operational and financial information, not indicating any immediate adverse events.
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- Tocagen Inc. (company) — Former company name
- March 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 3060 Pegasus Park Drive (address) — Principal Executive Offices
- (310) 618-6994 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Forte Biosciences, Inc.?
The 8-K filing reports on the company's Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhibits as of March 18, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 18, 2024.
What was Forte Biosciences, Inc. formerly known as?
Forte Biosciences, Inc. was formerly known as Tocagen Inc.
In which state is Forte Biosciences, Inc. incorporated?
Forte Biosciences, Inc. is incorporated in Delaware.
What is the business address of Forte Biosciences, Inc.?
The business address of Forte Biosciences, Inc. is 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-03-18 16:18:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
Filing Documents
- d784785d8k.htm (8-K) — 26KB
- d784785dex991.htm (EX-99.1) — 42KB
- d784785dex992.htm (EX-99.2) — 27KB
- g784785ex99_2p10g1.jpg (GRAPHIC) — 230KB
- g784785ex99_2p11g1.jpg (GRAPHIC) — 223KB
- g784785ex99_2p12g1.jpg (GRAPHIC) — 63KB
- g784785ex99_2p13g1.jpg (GRAPHIC) — 413KB
- g784785ex99_2p14g1.jpg (GRAPHIC) — 326KB
- g784785ex99_2p15g1.jpg (GRAPHIC) — 196KB
- g784785ex99_2p16g1.jpg (GRAPHIC) — 66KB
- g784785ex99_2p17g1.jpg (GRAPHIC) — 158KB
- g784785ex99_2p18g1.jpg (GRAPHIC) — 143KB
- g784785ex99_2p19g1.jpg (GRAPHIC) — 191KB
- g784785ex99_2p1g1.jpg (GRAPHIC) — 103KB
- g784785ex99_2p20g1.jpg (GRAPHIC) — 187KB
- g784785ex99_2p21g1.jpg (GRAPHIC) — 201KB
- g784785ex99_2p22g1.jpg (GRAPHIC) — 192KB
- g784785ex99_2p23g1.jpg (GRAPHIC) — 90KB
- g784785ex99_2p24g1.jpg (GRAPHIC) — 119KB
- g784785ex99_2p25g1.jpg (GRAPHIC) — 172KB
- g784785ex99_2p26g1.jpg (GRAPHIC) — 220KB
- g784785ex99_2p27g1.jpg (GRAPHIC) — 216KB
- g784785ex99_2p28g1.jpg (GRAPHIC) — 138KB
- g784785ex99_2p29g1.jpg (GRAPHIC) — 167KB
- g784785ex99_2p2g1.jpg (GRAPHIC) — 542KB
- g784785ex99_2p30g1.jpg (GRAPHIC) — 174KB
- g784785ex99_2p31g1.jpg (GRAPHIC) — 313KB
- g784785ex99_2p32g1.jpg (GRAPHIC) — 257KB
- g784785ex99_2p3g1.jpg (GRAPHIC) — 269KB
- g784785ex99_2p4g1.jpg (GRAPHIC) — 284KB
- g784785ex99_2p5g1.jpg (GRAPHIC) — 57KB
- g784785ex99_2p6g1.jpg (GRAPHIC) — 257KB
- g784785ex99_2p7g1.jpg (GRAPHIC) — 87KB
- g784785ex99_2p8g1.jpg (GRAPHIC) — 281KB
- g784785ex99_2p9g1.jpg (GRAPHIC) — 232KB
- g784785g0318081503852.jpg (GRAPHIC) — 5KB
- 0001193125-24-070158.txt ( ) — 9289KB
- fbrx-20240318.xsd (EX-101.SCH) — 3KB
- fbrx-20240318_lab.xml (EX-101.LAB) — 18KB
- fbrx-20240318_pre.xml (EX-101.PRE) — 11KB
- d784785d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated March 18, 2024 99.2 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: March 18, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer